Toxic workers cost companies to train replacements they drive away.
Fishing boats carrying decomposed corpses have washed ashore in Japan in recent weeks.
The distillery behind Ketel One Vodka, is now in its 11th generation.
Private equity firms face numerous challenges before making a profit.
German public prosecutor are looking into possible evaded tax payments linked to rigging of CO2 emissions.
Saudi Arabian women can now work dangerous jobs.
Taxi owners and lenders are suing New York City and its Taxi and Limousine Commission.
Shares of Valeant are falling after the call, as questions remain on Philidor, with CNBC's Meg Tirrell.
Shares of Volkswagen are down another 10 percent this week. Fmr. GM Chairman Bob Lutz, shares his perspective on the emission scandal, and VW's admission that it sold 800,000 cars in Europe that misstated fuel consumption and CO2 levels.
CNBC's Dominic Chu reports Citron says it is "not dialing back on its warning on Valeant, but are dialing back on the focus on Citron to investigate and report the vast spectrum of claims now piling up against Valeant."
Truckers are earning higher salaries amid the industry's shortage of drivers.
Silicon Valley blood testing start-up Theranos. CNBC contributor Jessica Lessin, Founder & Editor-in-Chief of The Information, discusses the questions surrounding the business model of Theranos, and the future for growing private tech companies.
New York Times' Jim Stewart, discusses Silicon Valley blood testing start-up Theranos.
Volkswagen's fault software could lead to 60 deaths in the U.S. by 2016
One Massachusetts man is getting billed $49,000 by a towing company after getting his Jeep pulled out of a mud pool.
Applebee's will pay a prep cook who didn't receiver checks for a year.
Goldman Sachs is expected to face a $50 million fine over a former bank employee's misuse of confidential information.
The Royal Bank of Scotland is on board with Facebook at Work, as the tech giant pushes its new workplace product into offices.
CNBC's Meg Tirrell reports that shares of Valeant Pharmaceuticals are bouncing back after tumbling more than 30 percent this week.
Valeant has a conference call scheduled for Monday morning. CNBC's Meg Tirrell reports the stock is rallying ahead of the call.